mirabegron

FDA Drug Profile — Mirabgeorn, MIRABEGRON, Mirabegron, Myrbetriq

mirabegron is listed in the FDA National Drug Code directory with 15 NDC codes, marketed under brand names including Mirabgeorn, MIRABEGRON, Mirabegron. Available dosage forms: tablet, film coated, extended release, granule, for suspension, extended release, powder.

Drug details

Generic Name
mirabegron
Brand Names
Mirabgeorn, MIRABEGRON, Mirabegron, Myrbetriq
Application Number
ANDA217989
Sponsor
Qilu Pharmaceutical Co., Ltd.
NDC Codes
15
Dosage Forms
TABLET, FILM COATED, EXTENDED RELEASE, GRANULE, FOR SUSPENSION, EXTENDED RELEASE, POWDER
Routes
ORAL
Active Ingredients
MIRABEGRON

Indications and Usage

1 INDICATIONS AND USAGE Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.